A systematic overview of VIP in experimental autoimmune encephalomyelitis (the MS product) observed that VIP administration minimized medical severity scores by forty–sixty five% across twelve independent reports, with histological Evaluation showing lowered CNS infiltration of Th1 and Th17 cells an